You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Risperidone Subcutaneous Implant

    SBC: DELPOR INC            Topic: 101

    The objective of the proposed study is to develop a subcutaneous implant of risperidone that provides consistent therapeutic blood levels of the drug for 6 months after a single administration. The device is implanted during a simple, 10-minute, in-office procedure with local anesthetic. The benefits of the product include improved medication adherence, fewer relapses, ability to withdraw the medi ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Developing and Evaluating In-Home Supportive Technology for Dementia Caregivers

    SBC: PEOPLE POWER COMPANY            Topic: NIA

    AbstractCaring for a loved one with Alzheimer’s disease, frontotemporal dementia, or another neurodegenerative disease is a highly meaningful part of family life. However, the associated burden and strain can have adverse effects on caregivers including mental and physical health problems, reduced well-being, and increased mortality. These effects, in turn, can compromise care quality and shorte ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Device to control circadian-effective light in Alzheimer's disease environments

    SBC: Blue Iris Labs            Topic: NIA

    Project Summary This proposed project will develop and field-test a device that accurately monitors and controls the circadian stimulus (CS) for Alzheimer disease (AD) and Alzheimer-disease-related dementia (ADRD) patients in nursing homes. Human biology has evolved to have two distinct optical systems: the visual system, by which we see and process images, and the circadian system, which regulate ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Rapid and Simple Paper Strip Test for the Multiplexed Detection of Gastrointestinal Pathogens at the Point-of-Need

    SBC: Godx Inc.            Topic: 950

    PROJECT SUMMARY GoDx, Inc. has been developing a prototype multiplexed paper strip device for the detection of the DNA and RNA of gastrointestinal pathogens at the point-of-need in andlt; 30 minutes with funding from the NCATS SBIR parent grant TR 001912. We have used the same platform technology we are developing in the parent grant to develop a rapid (andlt;30 minute), low-cost and instrument-fr ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. A scalable system for high-throughput and longitudinal electrophysiology in rodent brain research

    SBC: SPIKEGADGETS, INC.            Topic: 101

    Psychiatric disorders give rise to aberrant patterns of activity within the complex neural circuits of our brains. Yet, the exact nature of these abnormal patterns is often unknown to developers of new treatments. The goal of this project is to enable circuit-oriented research of neuropsychiatric diseases using rodent disease models. The long-term objective is to catalyze the discovery of new ther ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain

    SBC: SCARAB GENOMICS, LLC            Topic: NIAID

    Scarab Genomics has established a unique, tiny footprint, extended bacterial fermentation process enabled by its reduced genome E. coli, for production of protein therapeutics, especially vaccine conjugates. The process will massively reduce the cost and upgrade the quality of these critical vaccine components. This Phase IIB resubmission focuses on commercial development of Scarab’s first vacci ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD

    SBC: ACURASTEM INC            Topic: 101

    Optimization and validation of PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD Project Summary / Abstract The C9ORF72 repeat expansion mutation is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), accounting for over 50% of ALS cases in northern Europe and 10% of cases worldwide, making it a critical target for therapeutic intervention. Using patie ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Therapeutic Antibody for RSV IIB

    SBC: TRELLIS BIOSCIENCE, INC.            Topic: R

    Abstract Respiratory syncytial virus (RSV) is a leading cause of serious lower respiratory tract disease in infants, leading annually to ~200,000 deaths and 3-4 million hospitalizations worldwide. Close to $1 billion has been invested by the RSV community over the past two decades in clinical trials seeking to improve upon the marketed monoclonal antibody Synagis®, which is only approved for prop ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Senescence-Chips for Radiation Biodosimetry

    SBC: NEWOMICS INC.            Topic: NIAID

    Ideal biomarkers for acute and delayed radiation injury after a radiological/nuclear terrorist incident are those that arise and are measurable prior to manifestation of tissue injuries, typically one to a few days after ionizing radiation (IR) exposure. However, there are currently no commercial platforms that could perform assays for these biomarkers with high robustness, sensitivity, and specif ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Advancing a novel potent double anti-HCV nucleoside analog combination treatment for the OUD population to the clinic

    SBC: Riboscience LLC            Topic: NIDA

    Our goal is to develop an ultra short curative regimen for hepatitis C virus (HCV) infection in OUD patients. HCV is a major co-morbidity of many OUD patients. Treating their HCV reduces their subsequent IV drug use. While currently available regimens can cure HCV in most patients in 8-12 weeks, longer in patients with advanced liver disease or drug resistance mutations that are more frequent in O ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government